BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 17997145)

  • 1. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
    Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
    Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
    Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
    Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.
    Hamilton CA; Cheung MK; Osann K; Balzer B; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
    Gynecol Oncol; 2006 Nov; 103(2):679-83. PubMed ID: 16793126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma.
    Low JS; Wong EH; Tan HS; Yap SP; Chua EJ; Sethi VK; Soh LT; Low J; Tay EH; Chew SH
    Gynecol Oncol; 2005 Apr; 97(1):171-7. PubMed ID: 15790454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma.
    Einstein MH; Frimer M; Kuo DY; Reimers LL; Mehta K; Mutyala S; Huang GS; Hou JY; Goldberg GL
    Gynecol Oncol; 2012 Jan; 124(1):21-5. PubMed ID: 22035806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma.
    Obermair A; Mileshkin L; Bolz K; Kondalsamy-Chennakesavan S; Cheuk R; Vasey P; Wyld D; Goh J; Nicklin JL; Perrin LC; Sykes P; Janda M
    Gynecol Oncol; 2011 Feb; 120(2):179-84. PubMed ID: 21126755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
    Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
    Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
    Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; VillĂ  S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
    Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
    Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
    Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of chemotherapy and radiation in uterine papillary serous carcinoma.
    Viswanathan AN; Macklin EA; Berkowitz R; Matulonis U
    Gynecol Oncol; 2011 Dec; 123(3):542-7. PubMed ID: 21963091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
    Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
    Gynecol Oncol; 1999 Aug; 74(2):272-7. PubMed ID: 10419744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
    Thomas MB; Mariani A; Cliby WA; Keeney GA; Podratz KC; Dowdy SC
    Gynecol Oncol; 2007 Nov; 107(2):186-9. PubMed ID: 17688926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.
    Bristow RE; Asrari F; Trimble EL; Montz FJ
    Gynecol Oncol; 2001 May; 81(2):279-86. PubMed ID: 11330963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial.
    Frimer M; Miller EM; Shankar V; Girda E; Mehta K; Smith HO; Kuo DYS; Goldberg GL; Einstein MH
    Int J Gynecol Cancer; 2018 Nov; 28(9):1781-1788. PubMed ID: 30371562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
    Rauh-Hain JA; Growdon WB; Schorge JO; Goodman AK; Boruta DM; McCann C; Horowitz NS; del Carmen MG
    Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
    Bristow RE; Duska LR; Montz FJ
    Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.